Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma

• DOI: 10.1002/hed.24137
• Publication Date: 2015-05-28T15:50:37Z
• Authors: Luciano de Souza ...; Felipe Coelho de ...; Alexandre Andrade...; Danielle Calheiro...; Marcos Duarte de ...; Alexandre Arthur ...; Augusto Elias Mamere; Domingos Boldrini...; Renato de Castro ...; Carlos Roberto Sa...; Andre Lopes Carvalho
• Keywords: Regimen; Induction chemotherapy; Chemoradiotherapy

The purpose of this phase II trial was to evaluate the tolerability, safety, and efficacy a non-5-fluorouracil (5-FU)-based induction chemotherapy followed by chemoradiotherapy (CRT) for patients with locally advanced head neck squamous cell carcinoma (HNSCC).Sixty stage III IV HNSCC were treated paclitaxel cisplatin (TP; 175 mg/m(2) 80 , 3 cycles) CRT (cisplatin 100 ; D1, 22, 43 radiotherapy).Fifty-six (93.3%) completed cycles TP (no treatment-related deaths), 52 (86.7%) definitive per protocol (adverse event [AE] grade ≥2 in 53.3%). overall response rate after 82.5% resectable disease 55.5% unresectable (p = .023), complete (CR) 70.0% 30.0% .005).Induction based-CRT well-tolerated, safe, had high selected HNSCC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E970-E980, 2016.